Optimization of Cyclosporin therapy in atopic dermatitis through multiomic predictive models of treatment response (DermAtOmics)
- Conditions
- Adult, adolescent and paediatric patients with moderate-severe atopic dermatitisTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2022-500677-14-00
- Lead Sponsor
- Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
For cohort 1. Subjects diagnosed with moderate-severe atopic dermatitis who are going to receive treatment with cyclosporine., For Cohort 1 and 2. Participants must be willing and able to provide written informed consent prior the initiation of any study procedures, For Cohort 1 and 2. For children, parent/legal guardian must provide written informed consent. If age >11 years old, the minor must give assent., For Cohort 1 and 2. Participant is willing and able to adhere to the procedures specified in this protocol, For Cohort 2. Subjects diagnosed with moderate-severe atopic dermatitis who are receiving or have received in the past cyclosporine therapy.
Subjects participating in a clinical trial in the last three months., Any condition or situation precluding or interfering the compliance with the protocol., Women of childbearing potential must have a negative urine pregnancy test at Screening and Day 0., Women of childbearing potential must commit not to become pregnant
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method